Book Endometrial IHC Test in Saudi Arabia | Lahalak Medical Platform

An advanced diagnostic technique to accurately subtype endometrial cancer by detecting specific proteins like p53 and MMR, enabling physicians to tailor the most effective personalized treatment plans for patients.

Scientific name: Immunohistochemistry for Endometrial Carcinoma (IHC)

Advanced histopathological staining evaluating p53, PTEN, and MMR proteins in endometrial tissue. It classifies adenocarcinoma subtypes and guides adjuvant therapy decisions to improve clinical outcomes and patient survival.

Immunohistochemistry for Endometrial Carcinoma (IHC) - Precise Endometrial Cancer Subtyping
Service type Histopathology Laboratory Test
Duration 3-5 business days
Fasting Fasting is not required

Included Services

  • p53 protein staining
  • PTEN evaluation
  • MMR proteins panel
  • Detailed pathology report

Medical Service Information

Purpose of the Procedure

  • Accurate subtyping of endometrial adenocarcinoma.
  • Identifying eligibility for targeted immunotherapy.
  • Screening for Lynch syndrome through MMR protein testing.
  • Guiding adjuvant therapy decisions like chemotherapy or radiation.

Key Biomarkers Evaluated

  • p53 Protein: Distinguishes high-grade serous-like subtypes.
  • PTEN Protein: Evaluates cellular growth pathways.
  • MMR Proteins: Assesses DNA mismatch repair status for immunotherapy guidance.

When is this test required?

  • Following an initial diagnosis of endometrial cancer via biopsy.
  • For patients requiring personalized adjuvant treatment plans.
  • To assess potential hereditary cancer risks within the family.

Conditions & Notices

  • Requires a properly preserved tissue biopsy sample
  • Provide previous medical and pathology reports if available

Medical services you might also like